NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Beam Therapeutics Inc. (BEAM) Stock Analysis

Beam Therapeutics Inc. (BEAM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BEAM

$29.66

+$0.20 (+0.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BEAM with… →

BEAM Key Statistics

As of Sep 4, 2026
Trading
Open
$28.91
Previous Close
$29.46
Day's Range
28.91–29.97
52-Week Range
19.36–38.26
Volume
1.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.23
Valuation
Market Cap
$3.06B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
19.63
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.69
Financials (FY)
Revenue (FY)
$139.74M+120.01%
Net Income (FY)
−$79.99M
Profit marginThe share of revenue left as profit after all costs and taxes.
−55.45%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.29M
1-Year Return
+59.98%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
2.07M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BEAM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.00%
2025+11.77%
2024−8.89%
2023−30.40%
2022−50.92%
2021−2.39%
2020 (partial year)+335.41%

As of September 4, 2026.

BEAM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$139.74M−$79.99M−57.2%
2024$63.52M−$376.74M−593.1%
2023$377.71M−$132.53M−35.1%
2022$60.92M−$289.09M−474.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$139.74M—−$383.69M−$79.99M−57.2%
2024$63.52M—−$415.57M−$376.74M−593.1%
2023$377.71M—−$176.49M−$132.53M−35.1%
2022$60.92M—−$338.48M−$289.09M−474.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BEAM Valuation vs Biotechnology Median

Median of 656 stocks
MetricBEAMBiotechnology medianvs median
P/S ratio19.6315.2629% above
Profit margin−55.45%0.00%55.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Beam Therapeutics Inc. (BEAM) carries a market capitalisation of $3.06B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 540 employees.

The most recent close on file for BEAM is $29.66, dated September 4, 2026. That is +$0.20 (+0.68%) against the previous close. Over the past 52 weeks the price has ranged from $19.36 to $38.26. The latest close sits 53.24% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $139.74M. That is +120.01% against the prior fiscal year, when revenue was $63.52M. The same year closed with a net loss of $79.99M. Profit margin runs at −55.45%. That is 55.4 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.69.

Across the 4 fiscal years on file, revenue moves from $60.92M in 2022 to $139.74M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 19.63. On price-to-sales that is 28.63% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.23. Daily returns over the trailing 6 years annualize to a volatility of 78.05%. Over the trailing twelve months the price has returned +59.98%. Measured over 5 years, that is −23.41% a year compounded.

Growth & Income

The record shows no dividend for BEAM.

2026 is still running; the price is +7.00% year to date. Across the complete calendar years on file, 2025 returned +11.77% and 2022 returned −50.92%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Beam Therapeutics Inc. (BEAM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Beam Therapeutics Inc. BEAM $3.06B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Beam Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Visit website →